177Lu-TLX591

Phase 3

Telix Pharmaceuticals Ltd (TLX)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Metastatic Castration-resistant Prostate Cancer

ATNMATNM-400

LLY[Lu-177]-PNT2002

Phase 3

XNCRvudalimab monotherapy

Drug Information

Target Indication

Metastatic Castration-resistant Prostate Cancer

Clinical Trial

NCT06520345

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TLX

Telix Pharmaceuticals Ltd

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

68Ga-PSMA-11Phase 3

Biochemical Recurrence of Malignant Neoplasm of Prostate

89Zr-TLX250 PET/CTPhase 3

Clear Cell Renal Cell Carcinoma

PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CCPhase 2

Prostate Cancer

Zirconium Zr 89 GirentuximabPhase 2

Clear Cell Renal Cell Carcinoma

177Lu girentuximabPhase 2

Advanced Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts